Her suggestion could possibly lessen the burden on the government, which is grappling to get a measure of the exact cost to vaccinate the entire country and getting the logistics and supply chain in place to administer the vaccine. It is estimated that it could cost a minimum of Rs 50,000 crore to vaccinate the country.
“We expect momentum in the Biologics segment to continue with new market launches expected later in the year and increase penetrations in markets where our products have already been commercialized,” said Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon to analysts.
The government is calling it the "world's largest government healthcare scheme"--- the showpiece announcement of the Budget 2018 was a healthcare assurance scheme.
We are going to expand our biosimilars pipeline both with Mylan and Sandoz and beyond on our own, said Kiran Mazumdar Shaw, CMD, Biocon.
EBITDA Margins around 31-33% with focus on growth and investments are good, said Jonathan Hunt, CEO of Syngene International.
The company is trying to combine forces with companies who have been successful in biosimilars, said Kiran Mazumdar Shaw, CMD, Biocon.
Ajanta Pharma retains the tag of fastest wealth creator for the third time in a row and Asian Paints is the most consistent wealth creator, said the wealth creation study
In an interview to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon said Trastuzumab approval is a huge milestone. It has been under development for seven years.
European Medicines Agency (EMA) has accepted the Trastuzumab application for review. In an interview to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon spoke at length about the same.
In an interview to CNBC-TV18, Kiran Mazumdar Shaw, Chairperson & MD of Biocon spoke about the results and her outlook for the company.
In an interview to CNBC-TV18, Vishal Manchanda, Pharma Analyst at Nirmal Bang Institutional Equities shared his views and readings on the news as well as on Biocon stock.
Natco Pharma said it plans to utilize the cash flows generated by the launch of generic versions of Israel-based Teva’s top selling multiple sclerosis Copaxone 20 mg/ml and 40 mg/ml by its partner Mylan in US towards strengthening balance sheet and investing on business expansion.
Small booster for Biocon as they have received a certificate of good manufacturing practices (GMP) compliance from the European regulator for its insulin manufacturing facility in Malaysia.
“The request for withdrawal of the dossiers and re-submission is part of EMA procedural requirements linked to this re-inspection and will be considered by the EMA’s Committee for Medicinal Products of Human Use (CHMP),” the company said.
There appears to be a setback for Biocon as its biosimilars program hits a roadblock in Europe -- the drug products unit inspection done in March has not received the GMP certificate by the French regulator. In an interview to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon spoke about the latest happenings in the company.
Watch the interview of Kiran Mazumdar-Shaw, CMD of Biocon, Rakesh Biyani, Joint MD at Future Retail, Gnanesh Gala of Navneet Education, Harsh Mariwala of Marico, Bharat Madan, Group CFO at Escorts and KU Subbiah, CFO, VST Tillers Tractors in which they shared their views on how goods and services tax (GST) will impact businesses across the country.
Biocon chairperson Kiran Mazumdar-Shaw told Moneycontrol that the company is focusing on ramping up its biologics business, which accounts for 15 percent of overall revenues, but has the potential to be a game changer.
Biocon Chief Kiran Mazumdar Shaw says India is not an outsourced services country anymore, it is an innovation and knowledge partner.
Biotech company, Biocon will see two crucial inspections later this month and in early April. Company‘s manufacturing sites will come up for inspections by the European medicines agency later this month and next will be an inspection by the US FDA.
Biocon Thursday announced the US Food and Drug Administration has accepted Mylan‘s Biologics License Application (BLA) for biosimilar chemotherapy drug Pegfilgrastim for review. Sharing details on the development with CNBC-TV18 Biocon Chairperson and Managing Director Kiran Mazumdar Shaw said, "This is a very important acceptance."
Attributing the strong show in Q3FY17 to robust performance in biologics, Biocon Chairperson and MD Kiran Mazumdar-Shaw told CNBC-TV18 that Biocon is well poised to be front-runner in biosimilars. The acceptance of biosimilar Trastuzumab by the USFDA is a huge milestone for Mylan and Biocon, she said.
Following US president-elect Donald Trump‘s explosive speech last night where he lambasted the domestic pharma companies for outsourcing work, pharma stocks are likely to be in limelight today.
Biocon is among the companies that gave a good performance in 2016 and the stock surged 80 percent this year. Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of the company, said the company has gained traction in many emerging markets with its biosimilars.
Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon said huge opportunities exist for Biocon in the US biosimilars market.
In an interview with CNCB-TV18, Kiran Mazumdar Shaw, CMD of Biocon said that people worldwide are losing confidence in entrenched political systems and many feel marginalized and neglected from the economic developments that happen.